在小鼠中诱导过度活跃的阿片类抗原剂具有部分内在有效性和偏差的抗原作用,单独和与吗啡结合使用
Agnes Acevedo-Canabal1, Travis W Grim1, Cullen L Schmid1
1Department of Molecular Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology, Jupiter, FL 33458, USA.
Biomolecules
|June 28, 2023
概括
吗啡和芬太尼通过片受体 (MOR) 引起过度活跃. 新的非竞争性MOR激动剂可以减少这种过活性,同时促进疼痛缓解,显示受体疗效并不总是与药物效应相匹配.
科学领域:
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
- 分子生物学分子生物学
背景情况:
- 像吗啡和芬太尼这样的阿片类止痛药激活了片受体 (MORs).
- 这些药物可能会引起显著的副作用,包括过度活跃,这限制了它们的治疗用途.
- 了解受体活性与行为结果之间的关系对于开发更安全的止痛药至关重要.
研究的目的:
- 为了研究各种MOR激动剂在小鼠条体中的内在疗效.
- 确定受体水平疗效与行为结果 (如运动活动和反感应) 之间的关系.
- 探索偏向激动剂在调节传统阿片类药物的效果方面的潜力.
主要方法:
- 用S-GTPγS结合试验来测量小鼠条体中的G蛋白合有效性.
- 用小鼠的运动活动测试来评估体内药物疗效.
- 测试了不同MOR激动剂的组合,以评估它们的协同作用或对抗作用.
主要成果:
- 吗啡,芬太尼和奥利塞里丁在刺激G蛋白合方面表现出亚最大的内在疗效,但在促进运动活动方面完全有效.
- 非竞争性偏向性激动剂SR-17018和SR-15099显示出亚最大的过活性.
- 将SR-17018与吗啡结合使用减少了过活性和增强了抗受,而奥利塞里丁与吗啡增加了过活性.
结论:
- 非竞争性MOR激动剂可用于减轻阿片类药物诱导的过活性,并改善抗受体效应.
- 在受体水平上的内在疗效不是药物的疗效在行为测定如运动活动的直接预测器.
- 这些发现为开发更安全,更有效的阿片类药物疼痛疗法提供了潜在的战略.
相关概念视频
Opioid Receptors: Overview
1.1K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
1.1K
Analgesia and Pain Management
668
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
668
Drug-Receptor Interaction: Agonist
2.6K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.6K
Opioid Analgesics: Synthetic and Semisynthetic Opioids
347
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
347
Drug Abuse and Addiction: Pharmacological Phenomena
555
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
555
Adrenergic Agonists: Indirect-Acting Agents
1.7K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.7K


